Skip to Content

EULAR 2012 Investor Science Call

Roche conference call for investors and analysts from EULAR 2012

Investor Updates

  • Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy read more
  • Roche conference call for investors and analysts from EULAR 2012 read more

Webcast

Briefing

Roche conference call for investors and analysts from EULAR 2012

ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab.

The conference call took place on:

Friday, 8 June 2012

  • 5:30pm to 6:30pm (Central European Summer Time)
  • 4:30pm to 5:30pm (British Summer Time)
  • 11:30am to 12:30pm (Eastern Daylight Time)

Phone conference call

A replay of the conference call will be available one hour after the conference call and then for 48 hours. The replay can be accessed using the following dial-in numbers:

  • +41 (0)91 612 4330 (Europe)
  • +44 (0)207 108 6233 (UK)
  • +1 (1)866 416 2558 (USA)

Enter the ID 12079 followed by the # sign

At the time of the conference call, the accompanying presentation will be available from the IR website at http://ir.roche.com.